Precigen’s rare disease therapy gets full approval from the FDAnews2025-08-15T15:31:43+00:00August 15th, 2025|Endpoints News|
Autolus says it won’t make money from its cell therapy in Europe until 2027news2025-08-13T11:17:42+00:00August 13th, 2025|Endpoints News|
Treg biotech Abata Therapeutics closes as money runs shortnews2025-08-13T03:18:44+00:00August 13th, 2025|Endpoints News|
Fertility startup Gameto raises $44M to fund Phase 3 study of stem cell IVF therapynews2025-08-12T18:02:55+00:00August 12th, 2025|Endpoints News|
Iovance trims workforce after cell therapy sales missed expectationsnews2025-08-07T01:51:50+00:00August 7th, 2025|Endpoints News|
Elevidys sales fall again in Sarepta’s second quarter amid safety issuesnews2025-08-07T00:55:35+00:00August 7th, 2025|Endpoints News|
Beam delays key AATD readout, reveals plans to dose patients twicenews2025-08-05T17:58:24+00:00August 5th, 2025|Endpoints News|
Hansa says small trial shows its investigational drug could expand use of Sarepta’s Elevidysnews2025-08-04T11:29:29+00:00August 4th, 2025|Endpoints News|
Allogene says lymphodepletion drug caused patient death, changes CAR-T study designnews2025-08-01T12:30:30+00:00August 1st, 2025|Endpoints News|
4DMT’s eye gene therapy cuts need for injections that treat diabetic macular edemanews2025-07-31T20:41:21+00:00July 31st, 2025|Endpoints News|
